Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Skymount Medical US Inc. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently on file. This activity is confined to 1 distinct art unit, suggesting that the company's current patenting efforts are focused on a specific pharmaceutical or biological innovation. The prosecution is being handled by 1 distinct examiner, ensuring a consistent point of contact at the patent office. For a practitioner, this concentration means that the prosecution strategy can be highly specialized to the rules and trends of this single art unit.
The examiner RZECZYCKI, PHILLIP MATTHEW is the busiest examiner for the company, holding 1 busiest examiner pending office action. With only 1 distinct examiner involved, Skymount Medical US Inc. faces a centralized examination process where the interpretation of the 1 pending office action will be determined by a single individual. This structure minimizes the complexity often found in larger portfolios that span multiple art units and examiners. The alignment of the active portfolio within 1 distinct art unit suggests a streamlined approach to securing intellectual property in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283704 | USE OF MEBENDAZOLE FOR TREATING VIRAL INFECTION | RZECZYCKI, PHILLIP MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283704 | USE OF MEBENDAZOLE FOR TREATING VIRAL INFECTION | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103 | Final Rejection | — | Pending | Sep 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial